Following approval of hepatitis C virus protease inhibitors Incivek and Victrelis, companies are partnering to devise all-oral combination antiviral regimens without interferon α. But the virus is a long way from vanquished. Ken Garber investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kwong, A.D. et al. Nat. Biotechnol. 29, 993–1003. (2011).
Lok, A. et al. J. Hepatol. 54, Suppl. 1, S536, abstract 1356 (2011).
Fried, M. et al. AASLD annual meeting abstract LB-5 (2011).
Garber, K. Nat. Biotechnol. 25, 1379–1381 (2007).
Gao, M. et al. Nature 465, 96–100 (2010).
Tellinghuisen, T.L. et al. Nature 435, 374–379 (2005).
Chayama, K. et al. AASLD annual meeting abstract LB-4 (2011).
Ge, D. et al. Nature 461, 399–401 (2009).
Thomas, D.L. et al. Nature 461, 798–801 (2009).
Murray, C.L. & Rice, C.M. Nature 465, 42–44 (2010).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Hepatitis C: move over interferon. Nat Biotechnol 29, 963–966 (2011). https://doi.org/10.1038/nbt.2031
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2031
This article is cited by
-
FDA approvals usher in the post-interferon era in HCV
Nature Biotechnology (2014)
-
Gilead's $11 billion HCV bet
Nature Biotechnology (2012)
-
New Pharmacotherapy for Hepatitis C
Clinical Pharmacology & Therapeutics (2012)